A new exosome carrier could make oral CBD work more reliably
A microfluidic and mechanistic modeling approach to enhance oral bioavailability of cannabidiol via poloxamer-coated camel milk exosomes.
AI Summary
Cannabidiol (CBD) is difficult to deliver by mouth because it dissolves poorly in water, can be absorbed inconsistently, and is extensively processed by the liver before reaching the bloodstream. This study tested camel milk-derived exosomes coated with Poloxamer 407 as a nanoscale carrier designed to protect CBD in the stomach and release it gradually in the intestine. The coated particles remained stable, reduced early release under simulated gastric conditions, and supported controlled intestinal release. In laboratory cell models, the formulation also showed higher epithelial permeability than the control, with a reported Papp of 29.56 × 10⁻⁶ cm/s.
In rats, the coated exosome formulation increased systemic CBD exposure after oral dosing, reaching a Cmax of 719.58 ng/mL and an AUC₀–₂₄h of 2947.88 h·ng/mL. A custom microfluidic dissolution chip reproduced the same formulation ranking as conventional testing, while GastroPlus physiologically based pharmacokinetic modeling supported improved absorption, especially in the proximal small intestine. These results are proof-of-concept evidence, not evidence of improved effects or safety in people; the authors note that long-term stability, safety, reproducibility, and pharmacodynamic relevance still require further study.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.